TAK 573

Drug Profile

TAK 573

Alternative Names: TAK-573; TEV-48573

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class Antibodies; Antineoplastics; Interferons
  • Mechanism of Action CD38 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 09 Oct 2017 Phase-I/II clinical trials in Multiple myeloma (Monotherapy, Second-line treatment or greator) in USA (IV) (NCT03215030)
  • 11 Jul 2017 Millennium Pharmaceuticals plans a phase I/IIa trial in Multiple myeloma (Second-line therapy or greater, Monotherapy) in USA (IV, Infusion) (NCT03215030)
  • 11 Jul 2017 Preclinical trials in Multiple myeloma in USA (IV) before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top